ProQR Therapeutics N.V. PRQR
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 10.19M | 2.38M | 5.46M | 3.37M | 4.33M |
| Total Other Revenue | -- | -- | 32.60K | 38.60K | 179.30K |
| Total Revenue | 10.19M | 2.38M | 5.49M | 3.41M | 4.51M |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 10.19M | 2.38M | 5.49M | 3.41M | 4.51M |
| SG&A Expenses | 5.72M | 4.51M | 4.53M | 3.65M | 5.47M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 20.45M | 18.35M | 16.08M | 16.60M | 18.41M |
| Operating Income | -10.26M | -15.97M | -10.59M | -13.19M | -13.90M |
| Income Before Tax | -10.12M | -15.66M | -10.38M | -12.87M | -13.80M |
| Income Tax Expenses | 29.10K | -- | 1.20K | -- | 20.40K |
| Earnings from Continuing Operations | -10.15M | -15.66M | -10.38M | -12.87M | -13.82M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -10.15M | -15.66M | -10.38M | -12.87M | -13.82M |
| EBIT | -10.26M | -15.97M | -10.59M | -13.19M | -13.90M |
| EBITDA | -9.44M | -15.16M | -10.33M | -12.41M | -13.14M |
| EPS Basic | -0.09 | -0.15 | -0.10 | -0.12 | -0.13 |
| Normalized Basic EPS | -0.06 | -0.09 | -0.06 | -0.08 | -0.08 |
| EPS Diluted | -0.09 | -0.15 | -0.10 | -0.12 | -0.14 |
| Normalized Diluted EPS | -0.06 | -0.09 | -0.06 | -0.08 | -0.08 |
| Average Basic Shares Outstanding | 109.96M | 105.36M | 105.35M | 105.35M | 105.34M |
| Average Diluted Shares Outstanding | 109.96M | 105.36M | 105.35M | 105.35M | 105.34M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |